Emergency department presentations for chest complaints after mRNA COVID-19 vaccinations in children and adolescents
© 2023 The Authors. Emergency Medicine Australasia published by John Wiley & Sons Australia, Ltd on behalf of Australasian College for Emergency Medicine..
OBJECTIVE: To investigate characteristics and management of children presenting with chest complaints to a tertiary paediatric ED post-mRNA COVID-19 vaccine.
METHODS: This was a retrospective medical record review with data linkage to the Australian Immunisation Register. The study setting was the Royal Children's Hospital, Melbourne, Australia. Children <18 years who had a troponin blood test performed in hospital within 14 days of receiving mRNA COVID-19 vaccination were included. Elevated troponin and myocarditis or pericarditis as per Brighton criteria was the primary outcome. Vaccination status, length of stay, investigations and clinical management were secondary outcomes.
RESULTS: Six hundred and ten patients had a troponin test in 13 months. After exclusion of trauma-related tests (n = 31), known cardiac patients (n = 75) and others (n = 145), 359 troponins were obtained due to chest complaints and related symptoms, with 283 troponins assessed to be mRNA vaccination-related. There was a temporal peak in presentations with a 30-fold monthly increase in troponin post-commencement of mRNA COVID-19 vaccines. In those with chest complaints following mRNA vaccination, mean age was 14 years and 50.4% were female. Fourteen out of 283 (5%) vaccine-related troponins were abnormal with 14 patients assessed to have vaccine-associated myocarditis. No patients had pericarditis.
CONCLUSIONS: There was a large number of possible mRNA COVID-19 vaccine-related chest complaints presenting to the ED. Few patients had abnormal troponins or myocarditis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Emergency medicine Australasia : EMA - 36(2024), 1 vom: 02. Feb., Seite 110-117 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Parr, Mandy [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 19.01.2024 Date Revised 22.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1742-6723.14327 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363646094 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363646094 | ||
| 003 | DE-627 | ||
| 005 | 20240323000236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1742-6723.14327 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM363646094 | ||
| 035 | |a (NLM)37872323 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Parr, Mandy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emergency department presentations for chest complaints after mRNA COVID-19 vaccinations in children and adolescents |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2024 | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Emergency Medicine Australasia published by John Wiley & Sons Australia, Ltd on behalf of Australasian College for Emergency Medicine. | ||
| 520 | |a OBJECTIVE: To investigate characteristics and management of children presenting with chest complaints to a tertiary paediatric ED post-mRNA COVID-19 vaccine | ||
| 520 | |a METHODS: This was a retrospective medical record review with data linkage to the Australian Immunisation Register. The study setting was the Royal Children's Hospital, Melbourne, Australia. Children <18 years who had a troponin blood test performed in hospital within 14 days of receiving mRNA COVID-19 vaccination were included. Elevated troponin and myocarditis or pericarditis as per Brighton criteria was the primary outcome. Vaccination status, length of stay, investigations and clinical management were secondary outcomes | ||
| 520 | |a RESULTS: Six hundred and ten patients had a troponin test in 13 months. After exclusion of trauma-related tests (n = 31), known cardiac patients (n = 75) and others (n = 145), 359 troponins were obtained due to chest complaints and related symptoms, with 283 troponins assessed to be mRNA vaccination-related. There was a temporal peak in presentations with a 30-fold monthly increase in troponin post-commencement of mRNA COVID-19 vaccines. In those with chest complaints following mRNA vaccination, mean age was 14 years and 50.4% were female. Fourteen out of 283 (5%) vaccine-related troponins were abnormal with 14 patients assessed to have vaccine-associated myocarditis. No patients had pericarditis | ||
| 520 | |a CONCLUSIONS: There was a large number of possible mRNA COVID-19 vaccine-related chest complaints presenting to the ED. Few patients had abnormal troponins or myocarditis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a myocarditis | |
| 650 | 4 | |a paediatric | |
| 650 | 4 | |a pericarditis | |
| 650 | 4 | |a vaccinations | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Troponin |2 NLM | |
| 700 | 1 | |a Wilson, Catherine L |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Bryn |e verfasserin |4 aut | |
| 700 | 1 | |a Crawford, Nigel W |e verfasserin |4 aut | |
| 700 | 1 | |a Ferguson, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Ramesh, Sailavan |e verfasserin |4 aut | |
| 700 | 1 | |a Eapen, Nitaa |e verfasserin |4 aut | |
| 700 | 1 | |a Craig, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Hearps, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Babl, Franz E |e verfasserin |4 aut | |
| 700 | 0 | |a Paediatric Research in Emergency Departments International Collaborative (PREDICT) Research Network |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emergency medicine Australasia : EMA |d 2004 |g 36(2024), 1 vom: 02. Feb., Seite 110-117 |w (DE-627)NLM149139780 |x 1742-6723 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2024 |g number:1 |g day:02 |g month:02 |g pages:110-117 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1742-6723.14327 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2024 |e 1 |b 02 |c 02 |h 110-117 | ||